Diagnostic accuracy analysis of SARC‐F, its modified versions and the Quality of Life in Sarcopenia questionnaire in screening for sarcopenia in nursing home residents Authors: Hilal ŞİMŞEK, Aslı UÇAR Published: 2024 ABSTRACT AimSarcopenia, which is among the most important geriatric syndromes, is also a public health challenge. This study evaluated the performance of the SARC‐F, its modified versions and the Quality of Life in Sarcopenia (SarQoL) in screening for sarcopenia.MethodsIn the diagnostic accuracy study carried out with a total of 195 nursing home residents, sarcopenia was evaluated according to the European Working Group on Sarcopenia in Older Persons 2 algorithm. For SARC‐CalFs, the calf circumference standard and its population‐specific reference (31 cm, 32/33 cm, respectively) were used, whereas for SARC + elderly and body mass index information, age (>75 years) and body mass index (<21 kg/m2) were used. Screening test performance was evaluated with receiver operating characteristic analysis, and the optimal cut‐off points were determined according to the Youden index.ResultsThe prevalence of sarcopenia was 33.8%. Although SarQoL and SARC‐CalF scores were lower in individuals with sarcopenia, standard SARC‐F and SARC‐F + elderly and body mass index information scores were not different. SARC‐F had the poorest screening performance, whereas the SarQoL scale had the best screening performance (area under the curve 0.502 vs 0.787). SARC‐CalF (32/33 cm) had the best performance among the modified versions of SARC‐F. The optimal cut‐off point for SarQoL was <64.56, and its sensitivity in sarcopenia screening was 74.24% (95% CI 62.0–84.2) and its specificity was 79.07% (95% CI 71.0–85.7). All the modified versions of SARC‐CalF had higher sensitivity and area under the curve compared with SARC‐F.ConclusionsSarQoL screening performance might be conducive to providing clinical discrimination in a nursing home sample. Further research is needed for the use of SarQoL as a potential sarcopenia screening strategy. Additionally, SARC‐CalFs, especially the population‐specific SARC‐CalF (32/33 cm), might improve screening performance compared with standard SARC‐F. Geriatr Gerontol Int 2024; 24: 1335–1342. Introduction Sarcopenia, which was first defined as an “age‐related decrease in muscle mass” in 1989, 1 was included in the International Classification of Diseases in 2016. 2 Today, the global prevalence of sarcopenia, which is defined by the age‐related progressive decline in skeletal muscle mass and is considered among the most important geriatric syndromes, is estimated to vary between 10% and 27%, and the prevalence is expected to increase rapidly in the future with the aging population. 3 , 4 , 5 In addition to being one of the major geriatric syndromes, sarcopenia is also considered a public health challenge. The direct or indirect health effects of sarcopenia related to functional capacity, quality of life, independence, hospitalization, recovery period, or mortality are also among the prognostic factors of the increasing public health burden. 6 , 7 According to research carried out in this context, sarcopenia constitutes an important part of the global health economy by increasing healthcare costs with its direct and indirect costs. 7 , 8 Although research on the economic burden of sarcopenia is limited, it has previously been reported that it corresponds to 1.5% of national health expenditures in the USA, 9 the risk of hospitalization in the presence of sarcopenia approximately doubles (OR 1.95; 95% CI 1.47–2.59) and annual per capita health care costs increase by $2315. 10 Health screenings, which are considered one of the major elements of preventive health services, are becoming increasingly important due to the aging population and the increasing burden of geriatric diseases. Detecting the disease at a relatively early stage through effective screening means lower disease burden and healthcare costs. 11 , 12 Sarcopenia screening is of critical importance both for controlling the burden of geriatric disease in the aging population and for cost‐effectiveness analyses that can guide public health policies. 13 , 14 In this context, the main purpose of the screening tests applied is to reduce morbidity and mortality. 15 Among the tests used to screen for sarcopenia, the SARC‐F test is the most commonly used in clinical practice. This test is also included in the algorithm EWGSOP2 of the European Working Group on Sarcopenia in Older Persons (EWGSOP). 16 The SARC‐F test consists of five components: strength, assistance in walking, rising from a chair, climbing stairs and falls, which are determined by considering the effects of sarcopenia on functional capacity. In this test, whose scoring ranges from 0 to 10 points, a score of ≥4 out of 10 points indicates a risk of sarcopenia. 17 , 18 The main advantages of screening tests include being less invasive compared with diagnostic tests, and being cost‐ and time‐effective. In contrast, the screening test, by its nature, has a higher uncertainty than the diagnostic test. 19 Although its validity and reliability have been previously confirmed in many populations, including the Turkish population, 16 , 20 the performance of SARC‐F in detecting sarcopenia, especially in the early stages, in community‐dwelling older adults and nursing home residents has been controversial in the literature. 21 , 22 , 23 , 24 , 25 , 26 Therefore, in recent years, the diagnostic accuracy of modified versions of SARC‐F 27 , 28 , 29 , 30 or Quality of Life in Sarcopenia (SarQoL) 21 , 31 , 32 , 33 , 34 in sarcopenia screening has been examined in many studies. Previous studies have compared SARC‐F versus SarQoL in community‐dwelling older adults 21 or nursing home residents, 34 also, SARC‐F versus its modified versions in community‐dwelling older adults 27 or nursing home residents. 26 Therefore, the present study aimed to evaluate and compare the screening performances of SARC‐F, its modified versions and SarQoL all in the same sample of nursing home residents. This research hypothesized that the SarQoL overall score has a receiver operating characteristic (ROC) curve with a clinically significant (>0.7) under the curve (AUC area)value in sarcopenia screening. 35 Methods Study design and population The sample of the present cross‐sectional study consisted of 195 individuals who were aged>65 years and were living in a nursing home. The sample size was calculated in G*Power (Heinrich‐Heine‐University, Düsseldorf, Germany; software 3.1.9.7) 36 with at least 119 individuals to compare the performances of SARC‐F and SarQoL tests with a 5% significance level and 0.9 power (1‐β), using similar studies in the literature. 21 , 32 Included in the study were 195 individuals who met the following inclusion criteria: older adults having scored ≥23 on the cognitive function test Saint Louis University Mental Status Examination (SLUMS), had lived in a nursing home for at least 12 months and could use at least one hand for the measurement of handgrip strength. Older adults who were aged <65 years; had SLUMS test scores <23; had been diagnosed with any cognitive impairment/dementia, depression, kidney diseases or acute infection; and had any internal device or active malignancy were excluded from this study. All the participants signed the informed consent form. Measurements All anthropometric measurements were taken by trained personnel according to standard procedures. 37 Body composition was analyzed through bioelectrical impedance analysis using a Tanita SC330 body composition analyzer (Tanita Health, Tokyo, Japan), height was measured using a SECA 220 stadiometer that was fixed to the wall (Seca, Birmingham, UK), and mid‐upper arm and calf circumference measurements were measured with 0.1‐cm sensitivity using a non‐flexible tape. The body mass index (BMI) was calculated by dividing body weight (kg) by the square of height (m), and was evaluated according to the classification criteria recommended by the European Society for Clinical Nutrition and Metabolism. 38 Sarcopenia was defined according to the consensus of the EWGSOP2. Muscle strength was measured using a Takei T.K.K.5401 Grip‐D digital hand dynamometer (Takei Scientific Instruments, Niigata, Japan). Appendicular skeletal muscle mass was calculated by using the body resistance (ohms) measured by the bioelectrical impedance analysis technique in the equation validated by Scafoglieri et al. 18 , 39 The standard SARC‐F, its modified versions and the SarQoL scale were used to evaluate sarcopenia screening performances. The SARC‐CalF and SARC + elderly and body mass index information (EBM) evaluations, which are modified versions of the SARC‐F scale, were carried out as follows: The cut‐off points for SARC‐CalFs are the calf circumference standard (31 cm) 40 and the population‐specific reference value (32 cm in women, and 33 cm in men), 41 respectively. In both versions, 10 points were added to the standard SARC‐F score for calf circumference that is below the standard or reference, and the evaluation was made between 0 and 20 points. 30 , 42 SARC + EBM scoring is as follows: 10 points were added to the standard SARC‐F score for each criterion (age >75 years and BMI <21 kg/m2), and the evaluation was made between 0 and 30 points. 42 The SarQoL scale is a health‐related quality of life scale that evaluates dysfunction in seven subcategories as a result of a Likert grading of 55 items. An increasing score indicates a better quality of life, and is determined between 0 and 100. 43 As an inclusion criterion in the study, the SLUMS test was used to evaluate the cognitive functions of individuals. In this test, which is evaluated out of 30 points, scores below 23 are classified as mild cognitive impairment. 44 , 45 Statistical analysis All statistical analyses were carried out using SPSS (version 27.0; SPSS, Chicago, IL, USA) and MedCalc (version 19.2.6; MedCalc Software, Ostend, Belgium). The results are represented according to the data type, and parametric test assumptions mean (SD), median (interquartile range), and number and percentage. The χ2‐test was used to detect differences between the categorical variables, and the normal distribution of continuous variables was tested using the Kolmogorov–Smirnov test. The independent samples t‐test was used when the quantitative variables provided parametric test assumptions, whereas the Mann–Whitney U‐test was used it was not provided. The sensitivity and specificity of the SARC‐F test and SarQoL scale in detecting sarcopenia were examined by receiver operating characteristic (ROC) analysis. Screening test performance was evaluated with the area under the curve (AUC) and positive/negative likelihood ratios. A larger AUC indicates better overall diagnostic accuracy. The Fagan nomogram 46 was used to evaluate the likelihood ratios, and the Youden J statistic was used to determine the optimal cut‐off point. 47 All results were evaluated within the 95% confidence interval, and the significance level was P < 0.05. Results Characteristics of the study population The research was carried out with 129 non‐sarcopenic (66.2%) and 66 sarcopenic individuals (33.8%), a total of 195 nursing home residents. Although the groups' demographic characteristics and comorbidity criteria were similar, anthropometric measurements were lower in the sarcopenic group. In parallel with this result, BMI classification according to age was also different between the groups (P < 0.05; Table 1). According to Table 2, the SarQoL overall score and all the subscale scores were lower in the sarcopenic group. Although SARC‐F scores and classification did not differ between groups, modified SARC‐F scores according to calf circumference were found to be higher in the sarcopenic group (P < 0.05; Table 2). Table 1Characteristics and demographics of participantsSarcopenic (n = 66)Non‐sarcopenic (n = 129)Total (n = 195) P Sex (female), n (%)48 (72.7)75 (58.1)123 (63.1)0.046 a Age (years)77.00 ± 8.6379.31 ± 7.3678.58 ± 7.850.052 b Time living in the nursing home (years)5.00 (2.94)4.50 (5.00)5.00 (4.42)0.430 c Education (years)10.51 ± 4.4811.09 ± 4.6310.89 ± 4.570.411 b Marital status, n (%)0.148 a Married24 (36.4)34 (26.4)58 (29.7)Single/divorced/widowed42 (63.6)95 (73.6)137 (70.3)BMI (kg/m2)25.73 ± 4.7330.33 ± 5.1128.77 ± 5.43 0.000 ,b BMI classification d 0.000 ,a Underweight10 (15.2)1 (0.8)11 (5.6)Normal20 (30.3)14 (10.9)34 (17.4)Overweight29 (43.9)58 (45.0)87 (44.6)Obese7 (10.6)56 (43.4)63 (32.3)Calf circumference (cm)33.12 ± 3.0036.95 ± 3.5635.66 ± 3.83 0.000 ,b Handgrip strength (kg)18.29 ± 6.5521.43 ± 8.1620.37 ± 7.78 0.007 * ,b ASMI (kg/m2) e 6.54 ± 0.758.24 ± 1.727.67 ± 1.67 0.000 ,b No. chronic diseases2.61 ± 1.202.56 ± 1.332.58 ± 1.290.824 b No. medications5.98 ± 2.566.05 ± 3.036.03 ± 2.880.888 b Polypharmacy, n (%) f 52 (78.8)90 (69.8)142 (72.8)0.180 a Note: Data are presented as mean ± SD or median (IQR). The explanation has been added (p<0.05 highlighted in bold). Abbreviations: ASMI, appendicular skeletal muscle mass index; BMI, body mass index. a Pearson's χ2‐test; b Independent samples t‐test; c Mann–Whitney U‐test; d According to Cederholm et al. 38 ; e Calculated according to the equation of Scafoglieri et al. 39 f Defined as five or more drug usage daily.* P < 0,05; highlighted in bold. **P<0.001**ASMI, appendicular skeletal muscle mass index; BMI, body mass index. Characteristics and demographics of participants Note: Data are presented as mean ± SD or median (IQR). The explanation has been added (p<0.05 highlighted in bold). Abbreviations: ASMI, appendicular skeletal muscle mass index; BMI, body mass index. Pearson's χ2‐test; Independent samples t‐test; Mann–Whitney U‐test; According to Cederholm et al. 38 ; Calculated according to the equation of Scafoglieri et al. 39 Defined as five or more drug usage daily. P < 0,05; highlighted in bold. **P<0.001 ASMI, appendicular skeletal muscle mass index; BMI, body mass index. Table 2Scores of Quality of Life in Sarcopenia, SARC‐F and its modified versionsSarcopenic (n = 66)Non‐sarcopenic (n = 129) P SarQoL overall score58.04 (18.84)77.14 (27.51) <0.001, a D1 Physical and mental health58.87 (26.94)86.63 (17.76) <0.001, a D2 Locomotion58.78 (19.45)80.56 (36.11) 0.002 *, a D3 Body composition58.33 (22.92)83.33 (18.76) <0.001, a D4 Functionality63.87 (29.97)83.33 (28.02) 0.002 *, a D5 Activities of daily living51.76 (22.44)73.33 (40.00) <0.001, a D6 Leisure activities33.25 (16.63)49.88 (49.88) 0.032 * , a D7 Fears75.00 (21.00)87.50 (25.00) 0.024 *, a SARC‐F total score2.00 (3.00)2.00 (5.00)0.974 a Risk (≥4), n (%)15 (22.7)44 (34.1)0.138 b Normal (<4), n (%)51 (77.3)85 (65,9)SARC‐F + EBM c 11.00 (8.00)11.00 (7.00)0.927SARC‐F‐CalF‐31 d 3.00 (8.50)2.00 (5.00) 0.027 * SARC‐F‐CalF‐32/33 d 8.00 (9.00)2.00 (6.00) <0.001 ** Note: Data are presented as mean ± SD or median (interquartile range). Abbreviations: SarQoL, Quality of Life in Sarcopenia. a Mann–Whitney U‐test. b Pearson's χ2‐test. c EBM (elderly and body mass index information), SARC‐F results modified according to age and body mass index classification. d Modified SARC‐F results for standard (31 cm) and reference (32/33 cm) calf circumference measurements, respectively.* P < 0.05; highlighted in bold. **p<0.001 Scores of Quality of Life in Sarcopenia, SARC‐F and its modified versions Note: Data are presented as mean ± SD or median (interquartile range). Abbreviations: SarQoL, Quality of Life in Sarcopenia. Mann–Whitney U‐test. Pearson's χ2‐test. EBM (elderly and body mass index information), SARC‐F results modified according to age and body mass index classification. Modified SARC‐F results for standard (31 cm) and reference (32/33 cm) calf circumference measurements, respectively. P < 0.05; highlighted in bold. **p<0.001 Screening performance The performance of the SARC‐F screening test and its modified versions and the SarQoL quality of life scale for sarcopenia screening were evaluated by ROC analysis and shown in Table 3, and Figures 1 and 2. Accordingly, the SarQoL overall score had a significant diagnostic accuracy for screening for sarcopenia (AUC 0.787, P < 0.001). The diagnostic accuracy of SARC‐F and SARC + EBM total scores was not sufficient for sarcopenia screening. Both modified versions of SARC‐F for calf circumference (SARC‐F‐CalF‐31/CalF‐32/33; AUC 0.596 and 0.694, respectively) had significant diagnostic accuracy for screening sarcopenia (P < 0.05; Table 3). Although the AUC values of both SARC‐CalF versions and SarQoL have statistically significant diagnostic accuracy for screening, in the present study, SarQoL had the only AUC value (>0.7), showing clinical significance (Table 3). Table 3Receiver operating characteristic analysis for screening performances of Quality of Life in Sarcopenia, SARC‐F and modified screening testsAUC (95% CI)SE P a Youden index J (associated criterion) b Sensitivity (95% CI)+LR (95% CI)Specificity (95% CI)–LR (95% CI)SARC‐F0.502 (0.429–0.574)0.0400.9680.099 (>3)24.24 (14.5–36.4)0.71 (0.44–1.16)65.89 (57.0–74.0)1.15 (0.96–1.38)2003SARC‐F + EBM0.507 (0.435–0.579)0.0450.9740.098 (>17)72.73 (60.4–83.0)1.01 (0.84–1.21)27.91 (20.4–36.5)0.98 (0.60–1.58)SARC‐F‐CalF‐310.596 (0.524–0.666)0.044 0.027*0.23 (≥12)31.82 (20.9–44.4)3.73 (1.92–7.27)91.47 (85.3–95.7)0.75 (0.63–0.89)SARC‐F‐CalF‐32/330,694 (0.624–0.758)0.041 <0.001 ** 0.399 (≥12)53.03 (40.3–65.4)4.02 (2.45–6.62)86.82 (79,7‐92,1)0.54 (0.42–0.71)SarQoL0.787 (0.723–0.843)0.036 <0.001 ** 0.533 (≤64.56)74.24 (62.0–84.2)3.55 (2.46–5.11)79.07 (71.0–85.7)0,33 (0.21–0.50) Note: EBM (elderly and body mass index information), SARC‐F results modified according to age and body mass index classification; modified SARC‐F results for standard (31 cm) and reference (32/33 cm) calf circumference measurements, respectively. Abbreviations: AUC, area under the curve; LR, likelihood ratio; ROC, receiver operating characteristic; SarQoL, Quality of Life in Sarcopenia; SE, standard error. a Asymptotic significance for AUC. b Calculated according to the Youden J statistics.** P < 0 001; highlighted in bold. Receiver operating characteristic analysis for screening performances of Quality of Life in Sarcopenia, SARC‐F and modified screening tests Note: EBM (elderly and body mass index information), SARC‐F results modified according to age and body mass index classification; modified SARC‐F results for standard (31 cm) and reference (32/33 cm) calf circumference measurements, respectively. Abbreviations: AUC, area under the curve; LR, likelihood ratio; ROC, receiver operating characteristic; SarQoL, Quality of Life in Sarcopenia; SE, standard error. Asymptotic significance for AUC. Calculated according to the Youden J statistics. P < 0 001; highlighted in bold. Receiver operating characteristic curves for the Quality of Life in Sarcopenia (SarQoL), SARC‐F and its modified versions. Receiver operating characteristic curves for the Quality of Life in Sarcopenia (SarQoL), SARC‐F and its modified versions according to sex. (a) Men. (b) Women. The optimal cut‐off determined for SarQoL, and screening tests and the sensitivity and specificity values calculated according to these cut‐offs are given in Table 3. The cut‐off calculated according to the Youden index was found to be 64.56 for the SarQoL overall score. According to this value, the sensitivity of SarQoL in predicting sarcopenia is 74.24% (95% CI 62.0–84.2), whereas its specificity is 79.07% (95% CI 71.0–85.7). In contrast, there is lower sensitivity (24.24%) and specificity (65.89%) for the SARC‐F. Positive and negative likelihood ratios (+/− LR) similarly showed better performance for the SarQoL scale compared with the SARC‐F test. Modified versions of SARC‐F for calf circumference showed better performance than SARC‐F, but poorer performance than SarQoL (Table 3 and Fig. 1). Sex‐specific performance according to the ROC curves is presented in Figure 2, and the statistics for screening performance are presented in the supplementary material (Table S1 and S2). Accordingly, SarQoL and SARC‐CalF‐32/33 showed significant performance among men and women (P < 0.05). SARC‐CalF‐31 showed significant screening performance among men (AUC 0.692, P < 0.05), but not in women. Discussion In the present study, the diagnostic accuracy for screening of the SARC‐F, its modified versions and the SarQoL scale were evaluated. Although SARC‐F had the worst screening performance in the study, the SarQoL scale had the best screening performance. Additionally, SARC‐CalF (32/33 cm) was found to have the best performance among the modified versions of SARC‐F. The results of the study that anthropometric measurements (BMI, calf circumference, appendicular skeletal muscle mass index), muscle strength, and quality of life were lower in individuals with sarcopenia are consistent with many previous studies, and all of them are among the factors previously reported to be closely related to sarcopenia. 48 , 49 , 50 Another important point in this study is that the mean BMI was high in individuals with sarcopenia and in the total sample (total 28.77 ± 5.43 kg/m2). It has been reported in recent years that obesity is increasing in nursing home residents. However, the prevalence of obesity observed in this study is slightly higher than in previous studies (32.3% vs 16.7% and 28.0%). 51 , 52 In this context, the generalizability of the results is weak due to the sample characteristics. Considering that sarcopenia is characterized by both low muscle strength and mass, the difference in SARC‐F and SarQoL scores is an expected result. The basis of this relationship might be questions related to functional capacity in SARC‐F (e.g. strength, rising form a chair), whereas questions related to functionality and daily activities in SarQoL. Although there are no domains in SARC‐F, it has been observed that sarcopenic individuals have lower scores in SarQoL domains that are closely related to muscle strength and functionality (Table 2). Consistent with similar research carried out recently in a nursing home, 34 not only the SarQoL overall score, but all domains were found to be lower in individuals with sarcopenia. According to the present study, the diagnostic performance of neither SARC‐F nor SARC‐F + EBM had statistical significance. In contrast, according to previous studies, SARC‐F + EBM has better and statistically significant screening performance than standard SARC‐F (AUC >0,7). 29 , 30 , 35 , 42 Contrary to the literature, the fact that SARC‐F + EBM did not have a significant screening performance in this study might be a result of some significant differences between the research populations. The age that is part of the EBM scoring is high and above the cut‐off point (age 75 years) in the present study compared with other studies (mean age 69.4/72.0/74.2 vs. 78.6 years). In contrast, while the previous research populations were composed of community‐dwelling older adults or outpatients, this research was carried out in nursing home residents. Although it did not have sufficient clinical performance for screening, the research results are consistent with the literature that SARC‐F + EBM improves diagnostic accuracy compared with standard SARC‐F. 29 , 30 , 42 In the present study, SARC‐CalF‐32/33 was found to have the best diagnostic accuracy for screening performance among the modified versions of SARC‐F. Although both SARC‐F calf circumference‐modified versions have significant screening performance, it is an expected result that SARC‐CalF‐32/33, modified with the population‐specific reference (32/33 cm), showed better screening performance in this study carried out in the Turkish population (AUC 0.596 and 0.694, respectively). Similarly, as previously reported by Bahat et al., SARC‐CalF‐33 had better performance compared with SARC‐CalF‐31, and both calf circumference‐modified versions (SARC‐CalFs) had better AUC than the standard SARC‐F. However, in the same study, it was noted that in the modified versions of SARC‐CalF, the sensitivity is still poor (25%–50%) in community‐dwelling older adults. It has also been stated that SARC‐CalFs do not provide a significant advantage over SARC‐F in terms of diagnostic accuracy for screening in community‐dwelling older adults. 27 As a result of this study, although the performance of SARC‐CalFs according to AUC is promising in nursing home residents, this result should be interpreted carefully, as the sensitivity is still slightly poor (31.82% and 53.03%). Similarly, in other studies comparing SARC‐CalF screening performances in community‐dwelling older adults in Poland and Brazil, SARC‐CalFs that were modified according to the population reference value showed the best screening performance. 28 , 30 Previous studies on SARC‐CalF (31 cm) carried out in community‐dwelling older adults similarly reported sensitivity values lower than 50%, despite better performance than standard SARC‐F. 27 , 30 , 53 , 54 Based on these results, it can be said that although SARC‐CalFs cannot completely solve the problem of low sensitivity, they offer better screening performance compared with the standard SARC‐F by increasing sensitivity (better diagnostic accuracy), and the use of a population‐specific cut‐off point can increase the accuracy of the results. According to the present study, the sensitivity of the SarQoL scale in screening for sarcopenia is 74.24% (95% CI 62.0–84.2), whereas its specificity is 79.07% (95% CI 71.0–85.7). These values are close to the acceptable sensitivity level (~80%) for the clinical effectiveness of a screening test. 15 In contrast, there is lower sensitivity (24.24%) and specificity (65.89%) for the SARC‐F test. These results are consistent with previous studies reporting low‐to‐moderate sensitivity and high specificity for SARC‐F screening performance. 21 , 22 , 23 , 24 , 42 , 55 According to a similar study carried out by Geerinck et al., the sensitivity of SarQoL is higher than that of SARC‐F (64.7% and 52.4%, respectively), whereas its specificity is lower (80.5% and 86.6%, respectively). 21 Consistently, the AUC of SarQoL in this study had better screening performance, and this result was consistent with previous studies. 31 , 32 In the present study, sex‐specific screening performances were also examined and similar to the total sample, the SarQoL had the best performance, followed by SARC‐CalF‐32/33 in the analysis based on sex. Only one study was found in the literature that carried out a sex‐specific analysis in this context, and the performance of SarQoL was found to be significant (AUC 0.756) in sarcopenic obesity screening in older women. 31 In the present study, the cut‐off of the SarQoL scale for screening sarcopenia was determined as 64.56 points. This result, specific to the sample in the study, means that individuals with a SarQoL overall score below 64.56 are sarcopenic, whereas individuals with a result of this score or above are not sarcopenic. In previous studies, the cut‐off points calculated in studies on community‐dwelling older adults were 52.4 21 and 60 points, 31 , 32 whereas in a study carried out in a nursing home, it was found to be 58.5. 34 However, another important point is that, naturally, as SarQoL is a health‐related quality of life scale, the results regarding the cut‐off values for sarcopenia screening performance are still limited in the literature. As a health‐related quality of life scale, SarQoL offers a multifaceted assessment in line with its defined domains. SarQoL is promising, especially when considered in the context of the close relationship between activities of daily living and functionality with morbidity and mortality. 56 , 57 One of the important limitations of the SarQoL for use as a screening test is that it is a relatively long and comprehensive form. However, this assessment takes approximately 10 min. 58 Also, recently, the content validity of the SarQoL was examined in a study; the relevance, comprehensibility and comprehensiveness of the scale were evaluated as sufficient by both patients and sarcopenia experts. 59 All these data suggest that the future use of SarQoL or its combined versions with SARC‐F as a screening test merits more attention. Due to the cross‐sectional nature of the research and the fact that it was studied in a relatively special group, it is not possible to generalize the results obtained to the entire geriatric population. In contrast, the evaluation of severe sarcopenia according to the EWGSOP algorithm was not included in the scope of this study, and thus, comparison of severe versus sarcopenia was not possible. The strengths of this study include the fact that as a health‐related quality of life scale based on subjective evaluation was used, an exclusion criterion for individuals' cognitive functions (SLUMS <23) was used, and different potential screening tests were evaluated together. Early diagnosis and treatment of sarcopenia, one of the most important geriatric syndromes, is of critical importance in controlling the burden of geriatric disease and, therefore, in public health management. In this context, SarQoL might be an alternative approach to SARC‐F in screening sarcopenia according to EWGSOP2 criteria in nursing home residents. Disclosure statement The authors declare no conflict of interest. Author Contributions H.Ş. carried out conceptualization, design, data processing, analyzing and/or interpretation, literature review, and writing. A.U. carried out design, supervision and critical review. Ethics statement The ethical approval for this study was obtained from the Ankara University Ethics Commission, under number 56786525–050.04.04/505143. The study was carried out in accordance with the Declaration of Helsinki. The manuscript follows the Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) recommendations. Supporting information Data S1. Supporting Information.